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ABSTRACT
Objective. !e purpose of this research was 
to investigate whether changes in serum 
irisin levels can represent a marker of al-
tered energy requirements in patients with 
acute atrial "brillation (AF) undergoing 
cardioversion (CV).
Methods. !e research was planned as 
a randomized, prospective case-control 
study. Patients presenting to the emer-
gency medicine and cardiology depart-
ments of a university hospital due to acute 
AF were included in the study. Irisin levels 
were measured from serum specimens col-
lected 24 and 72 hours (h) following resto-
ration of sinus rhythm with CV in patients 
in AF rhythm. !e values obtained were 
then compared using statistical analysis. 
Results. !irty-one patients undergoing 
CV due to acute AF were enrolled. Mean 
irisin levels were studied from serum spec-
imens collected 24 and 72 h following res-
toration of sinus rhythm with CV, and were 
then compared. No statistically signi"cant 
di#erence was determined at comparison 
of patients’ basal to 24 h, basal to 72 h, and 
24 to 72 h mean irisin values (p=0.734, 
p=0.958, and p=0.643, respectively). Nega-
tive correlation was determined between 
basal serum irisin levels and LDL (r=-
0.519, p=0.002), but no signi"cant correla-
tion was observed with epicardial adipose 
tissue (EAT) thickness.
Conclusion. We determined no change in 
serum irisin levels studied 24 h and 72 h 
following return of normal sinus rhythm 
a$er CV from basal serum irisin levels in 
patients with acute AF. No correlation also 
was determined between serum irisin lev-
els and EAT thickness.
Key words: Atrial 4brillation, Irisin, Epicar-
dial adipose tissue, Cardioversion
INTRODUCTION
Atrial "brillation (AF) is the most com-
mon form of cardiac arrhythmia both 
worldwide and in Turkey and is seen in 
1-2% of the global population (1). Whether 
or not the body’s energy requirement has 
increased, is important in terms of treat-
ment planning in patients with AF and of 
explaining the body’s response to this form 
of arrhythmia. Some studies of energy me-
tabolism in patients with AF have reported 
that the AF rhythm increases energy de-
mand (2-5), while others have reported 
impaired energy production or consump-
tion (6-9). !ese inconsistent reports from 
the literature permit no de"nite conclusion 
regarding whether or not energy demand 
increases in the AF rhythm.
Irisin functions as an adenosine triphos-
phate (ATP) sensor in local tissues. If there 
is no energy requirement in the tissue, 
energy present in physiological irisin lev-
els is converted into heat, while if the tis-
sue requires ATP, then irisin production 
decreases. A low irisin level is thought to 
bestow some degree of protection against 
necrosis by inhibiting conversion of ATP 
into heat (10-12).
In order to investigate the relation between 
AF and energy metabolism, we planned 
to determine whether basal serum irisin 
levels in patients with AF would change 24 
and 72 hours (h) a$er cardioversion (CV). 
MATERIALS AND METHODS
Study Population
!is single-center, prospective study was 
performed in the emergency medicine and 
cardiology departments of a Turkish uni-
versity hospital. Following receipt of ethi-
cal committee approval (No. 2016/32), the 
study was conducted over an eight-month 
period between April and December, 2016. 
Patients undergoing medical or electrical 
CV procedures due to AF and in whom 
sinus rhythm was restored were included 
in the study. Patients with moderate or 
more severe heart valve disease, heart 
valve prosthesis, congenital heart disease, 
hypertrophic cardiomyopathy, permanent 
pacemaker, an ejection fraction lower than 
50%, or with uncontrolled or untreated 
thyroid function disorder, pregnant pa-
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tients and patients with kidney failure 
(creatinine >1.2 mg/dl), chronic liver dis-
ease, or diabetes, or aged under 18, were 
excluded.
One hundred forty-nine patients under-
going CV due to AF were evaluated. One 
hundred eighteen of these patients were 
excluded for various reasons. !e study 
was thus "nally conducted with 31 pa-
tients. !e patient selection scheme is 
shown in Figure 1. Selection of medical or 
electrical CV was based on European So-
ciety of Cardiology (ESC) 2016 guideline 
recommendations (1). All the patients in-
cluded in the study were hemodynamically 
stable, and medical or elective electrical 
CV was performed. No emergency electri-
cal CV was performed in any case.
All patients’ demographic characteristics, 
echocardiography (ECHO) "ndings, body 
mass index (BMI) values and CHA2DS2-
VASc scores at time of presentation were 
recorded onto study forms. Routine bio-
chemical parameters including glucose, 
creatinine, C-reactive protein (CRP), white 
blood cell count and platelet count ob-
tained by measuring hemoglobin, thyroid 
stimulating hormone (TSH), free thyrox-
ine (fT4), low-density lipoprotein (LDL), 
high-density lipoprotein (HDL), and total 
cholesterol and triglyceride levels were also 
recorded. 
Echocardiographic Evaluation
Transthoracic ECHO was performed at 
time of presentation on all patients with 
AF. Patients’ echocardiographic measure-
ments were obtained using a Vivid 7 (GE 
Vingmed Ultrasound, Horten, Norway) 
ECHO device. Le$ atrium (LA) diam-
eter, le$ ventricular end-systolic diam-
eter (LVESD) and end-diastolic diameter 
(LVEDD), and interventricular septum 
(IVS) and posterior wall (PW) thicknesses 
from parasternal long axis images together 
with epicardial adipose tissue (EAT) thick-
ness were measured. Ejection fraction 
was calculated from apical four chamber 
view using the modi"ed Simpson method. 
Right ventricle (RV) and right atrium (RA) 
diameters were measured. Pulmonary ar-
tery pressure (PAP) was measured with 
continuous Doppler %ow from the tricus-
pid valve jet. 
Serum Irisin Measurement
Two milliliters of serum was separated 
from blood collected from patients di-
agnosed with acute AF and placed into 
biochemistry tubes at time of presenta-
tion and during routine tests a$er 24 h 
and 72 h. !e serum specimens collected 
were stored at -80 ºC until the study was 
completed. Irisin levels were determined 
using an Enzyme-Linked Immunosorbent 
Assay (ELISA) kit (Elabscience, Cat No. 
RAG018R, Lot: X17-001, Czech Republic) 
in line with the manufacturing company’s 
instructions. Serum specimens in storage 
at -80 °C were brought to room tempera-
ture. Irisin standards were prepared in line 
with the kit procedures. Specimen absorb-
ances were read at a 450 nm wavelength on 
a VERSA (Designed by Molecular Devices 
in California, USA) microplate reader. !e 
results were expressed as μg/mL. Other 
biochemical parameters (glucose, creati-
nine, cholesterol, etc.) were measured us-
ing standard laboratory methods.
Statistical Analysis
Data analysis was performed on SPSS 23.0 
statistical so$ware. Descriptive statistics 
were expressed as number and percentage 
for categorical variables and as mean plus 
standard deviation for numerical variables. 
Normal distribution of numerical vari-
ables was assessed using the Kolmogorov-
Smirnov test. !e paired t test was used to 
compare normally distributed dependent 
variables. At correlation analysis, Pearson’s 
correlation test was used for normally dis-
tributed data, and Spearman’s correlation 
test for non-normally distributed data. Sta-
tistical signi"cance was set at p<0.05.
RESULTS
Patients’ mean age was 59.1±10.9 years; 
17 (54.8%) were women and 14 (45.2%) 
were men. Paroxysmal AF was present in 
21 (67.7%) patients and persistent AF in 
10 (32.3%). Fourteen (45.2%) patients re-
ceived medical CV and 17 (54.8%) electri-
cal CV. !e demographic characteristics of 
the patient groups are shown in Table 1.
Patients’ basal biochemical data and serum 
irisin values are shown in Table 2. Initial 
serum irisin levels measured with patients 
in AF rhythm were 7.68 ± 2.96 μg/mL, 
while 24-h values were 7.52 ± 2.56 μg/mL, 
and 72-h values were 7.71 ± 2.63 μg/mL. 
No statistically signi"cant di#erence was 
determined between basal and 24-n, basal 
and 72-h, or 24-h and 72-h serum irisin 
values (p=0.734, p=0.958, and p= 0.643). 
Correlations between patients’ basal serum 
irisin levels and clinical characteristics, 
ECHO "ndings, and laboratory "ndings 
are shown in Table 3. Signi"cant negative 
correlation was determined only between 
basal serum irisin levels and the lipid pa-
rameter LDL (r= -0.519, p= 0.002).  No 
signi"cant correlation was determined be-
tween basal serum irisin levels and other 
lipid parameters, BMI, ECHO "ndings, 
CHA2DS2-VASc score or EAT thickness.
!e e#ects on serum irisin levels of heart 
failure, hypertension, stroke and basic 
demographic characteristics, such as sex, 
were assessed separately, and no signi"cant 
e#ect of these parameters on serum irisin 
levels was observed. 
DISCUSSION
No statistically signi"cant di#erence was 
determined in our study between serum 
irisin levels during acute AF rhythm and 
at 24 h and 72 h a$er restoration of sinus 
rhythm via CV. Signi"cant negative cor-
Figure 1. Patient selection scheme 
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relation was determined only between 
patients’ basal serum irisin levels and the 
lipid parameter LDL. No signi"cant cor-
relation was determined between basal 
serum irisin levels and other lipid param-
eters, BMI, ECHO "ndings, CHADVASC2 
score or EAT thickness. Ours is the "rst 
study to investigate the relation between 
AF and irisin.
Irisin is released by heart and skeletal mus-
cle, the liver and kidney, the peripheral 
nerve sheath, and the dermis and hypoder-
mis (12). Heart muscle cells produce more 
irisin than skeletal muscles (13). Irisin has 
been identi"ed as a thermogenic protein 
responsible for energy consumption by 
converting white adipose tissue into brown 
adipose tissue. It activates the thermogenic 
function by increasing uncoupling pro-
tein-1 (UCP-1) expression in subcutane-
ous adipose tissue. Increased UCP1 re-
sults in heat production by reducing ATP 
synthesis, leading to greater consumption 
of energy resources (10,11). EAT, a brown 
adipose tissue found between the epicardi-
um and visceral layers of the pericardium, 
possesses high levels of UCP-1 and pro-
tects the myocardium against hypothermia 
by releasing fatty acid. Studies have shown 
that EAT thickness is correlated with the 
severity and incidence of AF (14,15). In-
%ammatory cytokines released from EAT 
are thought to contribute to the persistence 
of AF (10,12,16). In addition, studies of the 
relation between irisin levels and myocar-
dial infarction have determined that low 
irisin levels play a role in protecting myo-
cardial cells against energy loss (12,17).
In their experimental study, Kuloglu et al. 
determined low irisin levels in the "rst 24 
h of myocardial infarction (12). Aydin et 
al. observed a gradual decrease up to 48 h 
in saliva and serum irisin levels in acute 
myocardial infarction patients, and report-
ed that levels began rising a$er 72 h (17). 
While it is possible that serum irisin levels 
decrease gradually for the "rst 48 h follow-
ing CV and establishment of sinus rhythm 
in AF, and that they subsequently begin 
increasing, through the same mechanism, 
a$er 72 h, our "ndings do not support this 
hypothesis. We determined no signi"cant 
change in irisin levels at 24 h and 72 h 
post-CV.  
Sahin et al. determined signi"cantly higher 
serum irisin levels and EAT thickness in 
hyperthyroid patients compared to a con-
trol group, and that EAT was positively and 
independently correlated with serum iri-
sin. !ose authors reported that metabolic 
Table 1. Baseline characteristics of acute AF patients
Variables Acute AF (n=31)






BMI (kg/m²); mean ± SD 31.35±6.3















CHA2DS2-VASc score; mean ± SD 1.71±1.37




LA diameter (mm) 
IVS thicknesses (mm) 
PW thicknesses (mm) 
RV diameter (mm) 
RA diameter (mm) 
sPAP 











Cardioversion type; n (%)
Medical 14(45.2%)
Electrical 17(54.8%)
AF:Atrial "brillation, BMI:Body mass index, ECHO:Echocardiography, 
IVS:Interventricular septum, LA:Le$ atrium, LVEDD:Le$ ventricular end-diastolic di-
ameter, LVEF: Le$ ventricular ejection fraction, LVESD:Le$ ventricular end-systolic di-
ameter, PW:Posterior wall, RA:Right atrium, RV:Right ventricle, SD:Standard deviation, 
sPAP:Pulmonary artery pressure, TIA:Transient ischemic attack
Table 2. Patients’ basal laboratory 4ndings and serum irisin levels 
Variables Acute AF (n=31)
Laboratory "ndings; 
Glucose ( mg/dL) 
Creatinine (mg/dL) 
TC (mg/dL)
TG  (mg/dL) 
LDL-c  (mg/dL) 


























p value between a and b=0.734, p value between a and c=0.958, p value between b and 
c=0.643. AF:Atrial "brillation, CRP:C-reactive protein, fT4:Free thyroxine, HDL-c:High-
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disorders such as increased basal metabol-
ic rate and thermogenesis in hyperthyroid 
status might be indirectly associated with 
an increase in EAT and serum irisin levels 
(18). However, our "ndings are not com-
patible with those of Sahin et al. Although 
our patient group also consisted of acute 
AF patients with a high basal metabolic 
rate, we observed no signi"cant change in 
irisin levels in acute AF and following res-
toration of a normal sinus rhythm with CV. 
Kaneda et al. reported negative correla-
tion between serum irisin levels and EAT 
in patients undergoing cardiovascular sur-
gery (19). However, Sahin et al. reported 
positive correlation between irisin levels 
and EAT thickness, while we observed no 
signi"cant correlation. !ese "ndings in-
dicate that further studies are now needed 
to investigate the relation between EAT 
thickness and serum irisin levels.
We observed no correlation between BMI 
and serum irisin levels in the present study. 
Although Sahin et al. and Kaneda et al.’s 
results support our "nding, other studies 
have reported a positive correlation be-
tween BMI and irisin levels (10,20), while 
Moreno-Navarette et al. determined nega-
tive correlation (21). Although we deter-
mined signi"cant negative correlation only 
between basal irisin levels and the lipid pa-
rameter LDL, we observed no signi"cant 
correlation with total cholesterol, triglyc-
eride or HDL. Sahin et al. and Kaneda et 
al. reported no correlation between serum 
irisin and any lipid parameter, although 
other studies have reported positive cor-
relation between irisin and LDL and total 
cholesterol (22). Based on these "ndings, it 
is impossible to draw any de"nite conclu-
sion concerning the relation between se-
rum irisin and BMI and lipid parameters.
LIMITATIONS
!e main limitation to our study is the 
relatively low number of patients enrolled. 
!e second limitation is that the data could 
not be compared against a healthy control 
group. Additionally, serum irisin values 
were not investigated 48 h a$er CV. 
 
CONCLUSION
We determined no change in acute AF pa-
tients’ basal irisin levels and those at 24 h 
and 72 h following restoration of normal 
sinus rhythm a$er CV procedures. In ad-
dition, our "ndings revealed no correlation 
between AF patients’ EAT thickness and 
serum irisin levels. More extensive studies 
are now needed for a better understand-
ing of the association between serum irisin 
levels and AF and EAT.
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